By: ChinaBio® Today
February 12, 2013 at 06:15 AM EST
Celgene Gains SFDA Approval for Multiple Myeloma Treatment
Celgene Corporation was granted approval for Revlimid ® (lenalidomide) by the SFDA for Revlimid ® (lenalidomide) to treat multiple myeloma. The approval, which is the first for Celgene in China, includes an Import Drug License. Revlimid is indicated for use in combination with dexamethasone in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. In 2006, the drug was approved for a similar indication in the US. More details.... Stock Symbol: (NSDQ: CELG) Share this with colleagues: // //
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here